EMA CHMP give positive opinion to Amgen’s Bekemv® eculizumab biosimilar

Feb 23, 2023

The EMA CHMP has recommended a grant of market authorization for Bekemv®, Amgen’s eculizumab biosimilar to Alexion’s Soliris® (eculizumab). Bekemv is indicated for the treatment of paroxysmal nocturnal haemoglobinuria in adults and children.

Print Page Mail Article